Investigation Report on China Acarbose Market, 2010-2019

Diabetes is one of the most important chronic non-communicable diseases that threaten health of people around the world. According to the statistics of International Diab…
Reference: 1505184
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
5/28/2015
Pages
30
Version:
2010
Charts:
30
Language
  • English
  • Chinese
Format
License

Description

Diabetes is one of the most important chronic non-communicable diseases that threaten health of people around the world. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. With the improvement of living standards and the change of life styles in China, the incidence of diabetes has kept growing and the market size of diabetes drugs has expanded each year, exceeding CNY 20 billion in 2014 according to CRI’s research.
Acarbose, a kind of α-glucosidase inhibitors developed by Bayer, first came into German market in 1990 and then entered the markets of many countries after getting FDA’s approval on Sep.6, 1995. Acarbose, a kind of complex carbonhydrate, is a α-glucosidase inhibitor which can competitively inhibit α-glucosidase in brush border of cells in intestinal wall and defer hydrolysis of disaccharide and polysaccharide, thus effectively reducing postprandial glycemia. Acarbose can not only reduce postprandial glycemia, fasting glucose, hemoglobin (HbA1c) significantly but also is weight neutral or leads to slight weight loss. When it is used together with sulfonylurea or insulin, the impacts of weight gain can be mitigated.
Since Acarbose entered Chinese market in 1995, its sales have kept growing for two decades. According to CRI’s market survey, its sales in 2014 was about CNY 739 million and the CAGR during the period of 2005-2014 was about 13.7%.
Currently, Bayer’s products have taken up 70% of Acarbose market in China while and Sichuan Luye Bao Guang Pharmaceutical Industry Co., Ltd claim the rest market share.
CRI estimates that in the next few years, as the incidence of diabetes and the number of diabetes patients keep going up in China, the market size of Acarbose will enjoy a sustained growth.

Readers can get at least the following information through this report:
-market size of Acarbose in China
-major manufacturers of Acarbose for Chinese market and their market share
-retail price of Acarose in Chinese market
-market outlook of Acarbose in China

The author suggests the following groups of people purchase this report:
-manufacturers of antidiabetic drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in medicine market, please contact CRI for customized survey service

Table of Contents

1 Related Concepts of Acarbose
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Acarbose in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Sales Status of Acarbose in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Regional Sales Value
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Regional Sales Volume

4 Survey on Market Share of Major Manufacturers of Acarbose in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Acarbose in China
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Acarbose in Chinese Hospitals in 2014
6.1 Beijing Bayer Healthcare
6.2 Sichuan Luye Bao Guang Pharmaceutical Industry Co., Ltd
6.3 Bayer Group (Germany)
6.4 Zhejiang Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd

7 Major Manufacturers of Acarbose for Chinese Market, 2010-2014
7.1 Beijing Bayer Healthcare
7.2 Zhejiang Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
7.3 Sichuan Luye Bao Guang Pharmaceutical Industry Co., Ltd
7.4 Bayer Group (Germany)

8 Market Outlook of Acarbose in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Patent Registration Information of Acarbose in China
Chart Approval Status of Acarbose in China
Chart Sales Status of Acarbose in China, 2010-2014
Chart Sales Value of Acarbose in China, 2010-2014 (unit in CNY million)
Chart Sales Value of Acarbose by Regions in China (unit in CNY million)
Chart Sales Volume of Acarbose in China, 2010-2014 (unit: million)
Chart Sales Volume of Acarbose by Regions in China, 2010-2014
Chart Market Share of Major Manufacturers of Acarbose by Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Acarbose Made by Beijing Bayer, 2010-2014
Chart Sales Value and Market Share of Acarbose Made by Hangzhou Zhongmei Huadong, 2010-2014
Chart Sales Value and Market Share of Acarbose Made by Sichuan Luye Bao Guang, 2010-2014
Chart Price of Acarbose (Glucobay) Made by Beijing Bayer Healthcare in Some Cities in China, 2014
Chart Price of Acarbose (Bei Xi) Made by Sichuan Luye Bao Guang Pharmaceutical Industry Co., Ltd in Some Cities in China, 2014
Chart Price of Acarbose (Ka Bo Ping) Made by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd in Some Cities in China, 2014
Scroll